| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | William W Busse | Q57330018 |
| P2093 | author name string | Ravi K Viswanathan | |
| P2860 | cites work | Suppression of late-phase skin reactions by immunotherapy with ragweed extract | Q93634268 |
| Injection allergen immunotherapy for asthma | Q24236566 | ||
| Allergen injection immunotherapy for seasonal allergic rhinitis | Q24243115 | ||
| Sublingual immunotherapy for allergic rhinitis | Q24248657 | ||
| Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study | Q25255771 | ||
| Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial | Q28248578 | ||
| Immunological mechanisms of allergen-specific immunotherapy | Q28265326 | ||
| Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method | Q33255883 | ||
| Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. | Q33550915 | ||
| Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 | ||
| Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study | Q34005065 | ||
| Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma | Q34098997 | ||
| The health economics of asthma and rhinitis. I. Assessing the economic impact | Q34125902 | ||
| Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. | Q34170327 | ||
| Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. | Q34480913 | ||
| Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials | Q34561153 | ||
| World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) | Q34589248 | ||
| Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa | Q34590830 | ||
| Allergic rhinitis and its impact on asthma update: allergen immunotherapy | Q34617277 | ||
| Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper | Q34754637 | ||
| The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis | Q35005943 | ||
| The burden of allergic rhinitis | Q36772690 | ||
| Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? | Q36829985 | ||
| Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. | Q36977154 | ||
| Multiallergen immunotherapy for allergic rhinitis and asthma | Q37393341 | ||
| Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study | Q37689682 | ||
| A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract | Q72876300 | ||
| A controlled trial of immunotherapy for asthma in allergic children | Q73020915 | ||
| Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy | Q73265462 | ||
| Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies | Q74237112 | ||
| Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients | Q74295467 | ||
| Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis | Q77633152 | ||
| Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study | Q77827539 | ||
| Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study | Q79429550 | ||
| Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression | Q79985014 | ||
| Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite | Q80221271 | ||
| Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study | Q80378144 | ||
| Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study | Q80488569 | ||
| Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France | Q80601052 | ||
| Prevalence and rate of diagnosis of allergic rhinitis in Europe | Q80936964 | ||
| Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract | Q81092763 | ||
| Mechanisms of allergen-specific immunotherapy | Q83143842 | ||
| Health economics of allergen-specific immunotherapy in the United States | Q83143854 | ||
| Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma | Q83842404 | ||
| Immunotherapy with peptides | Q83911230 | ||
| Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties | Q84491603 | ||
| Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. | Q37776915 | ||
| Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. | Q37802050 | ||
| Immunotherapy: The meta-analyses. What have we Learned? | Q37870447 | ||
| Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses | Q37881087 | ||
| Mechanisms of immunotherapy to aeroallergens | Q37901536 | ||
| Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study | Q39017587 | ||
| Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma | Q39515670 | ||
| Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study | Q39581669 | ||
| Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis | Q40486781 | ||
| Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood | Q40488834 | ||
| Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis | Q40523833 | ||
| Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study | Q40544021 | ||
| Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 | ||
| Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial | Q40609682 | ||
| Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. | Q40656273 | ||
| Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. | Q40668250 | ||
| Ragweed immunotherapy in adult asthma | Q40672079 | ||
| Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells | Q40749921 | ||
| Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity | Q41745934 | ||
| Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study | Q42595535 | ||
| Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma. | Q43077853 | ||
| Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. | Q43724345 | ||
| The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey | Q44051269 | ||
| Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study | Q44095490 | ||
| IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy | Q44429951 | ||
| Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. | Q44467274 | ||
| Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study | Q44692876 | ||
| Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity | Q46675736 | ||
| Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis | Q46892026 | ||
| Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma | Q46930354 | ||
| Wasp venom immunotherapy changes IgG antibody specificity | Q47788110 | ||
| Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis | Q47804869 | ||
| Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy | Q48713439 | ||
| Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet | Q48897904 | ||
| Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. | Q50621222 | ||
| Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study. | Q51147222 | ||
| Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. | Q51175045 | ||
| Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. | Q51718271 | ||
| Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. | Q51966464 | ||
| Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. | Q52090255 | ||
| Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. | Q52455489 | ||
| Allergen immunotherapy: a practice parameter third update. | Q52712682 | ||
| Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. | Q53179735 | ||
| Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. | Q53988360 | ||
| Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. | Q54420300 | ||
| Effective hyposensitization in allergic rhinitis using a potent partially purified extract of house dust mite | Q70251405 | ||
| Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy | Q70347566 | ||
| Dose response of IgE and IgG antibodies during ragweed immunotherapy | Q71000955 | ||
| Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study | Q71620176 | ||
| Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study | Q71861032 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 1303-1314 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses | |
| P478 | volume | 141 |
| Q35564301 | "The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis". |
| Q38912244 | Allergen immunotherapy: routes, safety, efficacy, and mode of action |
| Q38113269 | Allergen-specific immunotherapy in asthmatic children: from the basis to clinical applications |
| Q54937942 | Allergy immunotherapy restores airway epithelial barrier dysfunction through suppressing IL-25 -induced endoplasmic reticulum stress in asthma. |
| Q47149942 | Chinese Guideline on allergen immunotherapy for allergic rhinitis |
| Q38247821 | Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience |
| Q38542919 | Focusing the mechanism of action to dissect the different treatments of respiratory allergy |
| Q37679681 | Respiratory allergies: a general overview of remedies, delivery systems, and the need to progress |
| Q36935177 | Severe asthma: an expanding and mounting clinical challenge |
| Q40790855 | Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis |
| Q37034096 | Sublingual delivery of vaccines for the induction of mucosal immunity |
| Q27002341 | Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines |
| Q30440195 | Sublingual immunotherapy: World Allergy Organization position paper 2013 update |
| Q24601352 | Sublingual vs oral immunotherapy for food allergy: identifying the right approach |
| Q35645654 | The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey |
| Q35528924 | Vaccine development and new attempts of treatment for ragweed allergy |
Search more.